Exact Sciences Corporation (EXAS)

Market Cap	10.40B
Revenue (ttm)	2.69B
Net Income (ttm)	-214.04M
Shares Out	185.08M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	448,158
Open	57.16
Previous Close	57.55
Day's Range	55.61 - 57.23
52-Week Range	40.62 - 79.62
Beta	1.23
Analysts	Strong Buy
Price Target	72.80 (+29.54%)
Earnings Date	Feb 19, 2025

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Co...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1995
• Employees: 6,600
• Stock Exchange: NASDAQ
• Ticker Symbol: EXAS
• Website: https://www.exactsciences.com

Financial Performance

In 2023, Exact Sciences's revenue was $2.50 billion, an increase of 19.93% compared to the previous year's $2.08 billion. Losses were -$204.15 million, -67.26% less than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price forecast is $72.8, which is an increase of 29.54% from the latest price.

Price Target

$72.8

(29.54% upside)

Analyst Consensus: Strong Buy